



**YANG YANG CHINA  
HOLDINGS LIMITED**  
A B N 2 1 1 0 9 4 6 9 3 8 3

Friday, June 22, 2007

**By E LODGEMENT**

National Stock Exchange of Australia Limited  
Ground Floor 384 Hunter Street  
Newcastle NSW 2300

**NEWS-TRADING HALT**

As disclosed in the meeting documentation lodged with NSX on 16 May 2007, the company is holding, on 26<sup>th</sup> June 2007, the various meetings in relation to the change of operations of the company and the selective buy back of the company's majority shareholder. For more details in relation to this meeting please refer to the announcement by the company of 16 May 2007 or contact the company's office.

The board of the company has decided, in accordance with industry practice, to place the company in a trading halt prior to the meeting. The details are as follows:

Monday 25 <sup>th</sup> June 2007	Trading Halt
Tuesday 26 <sup>th</sup> June 2007	Trading Halt
Wednesday 27 <sup>th</sup> June 2007	Normal Trading Resumes once the results of the meeting are disclosed to the market.

The directors look forward to seeing all shareholders at the various meetings.

**About Yang Yang**

Yang Yang China Holdings Limited is an internationally bio-technology company focused on developing its proprietary LETU lactobacillus. Yang Yang is listed on the Stock Exchange of Newcastle and has its operations in Guangzhou Province, China and Sydney, Australia. Its lead programs involve the licensing of farms in both Australia and China to use LETU lactobacillus in animal feed. For additional information please contact the company on +61-2-9327 7373.

**Yang Yang Forward-looking Statements**

This press release contains forward-looking statements that reflect the Company's current expectations regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including the success of the Company's research strategy, the applicability of the discoveries made therein, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process.